Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license
A Chicago biotech claims in a new lawsuit that Cambridge venture capital firm Third Rock Ventures and bluebird bio CEO Nick Leschly worked to hinder its drug development efforts so it could more easily obtain a key part of its intellectual property.
Errant Gene Therapeutics is suing Third Rock Ventures and Leschly three years after it sued New York-based Sloan Kettering Memorial Cancer Center over a stalled rare disease trial.
In the lawsuit, filed on Friday in Suffolk County Superior Court, Errant…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Allison DeAngelis Source Type: news
More News: American Health | Biotechnology | Cancer | Cancer & Oncology | Gene Therapy | Genetics | Health Management | Lawsuits | Legislation | Rare Diseases | Venture Capital